Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Phase 1/2 Terminated
53 enrolled 22 charts
topMIND
Phase 1/2 Terminated
54 enrolled 23 charts
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
Phase 1/2 Completed
16 enrolled 14 charts
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
15 enrolled 15 charts
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Phase 1/2 Completed
24 enrolled 18 charts
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1/2 Terminated
57 enrolled 31 charts
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Phase 1/2 Completed
171 enrolled 23 charts
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
Phase 1/2 Completed
32 enrolled 23 charts
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Phase 1/2 Completed
247 enrolled 15 charts
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Terminated
9 enrolled 11 charts
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
Phase 1/2 Terminated
79 enrolled 18 charts
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Phase 1/2 Terminated
12 enrolled 13 charts
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Phase 1/2 Terminated
43 enrolled 15 charts
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
6 enrolled 10 charts
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Phase 1/2 Completed
36 enrolled 26 charts
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Phase 1/2 Terminated
9 enrolled 13 charts
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Phase 1/2 Completed
27 enrolled 13 charts
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
Phase 1/2 Completed
49 enrolled 12 charts
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Phase 1/2 Terminated
7 enrolled 11 charts
PIL
Phase 1/2 Terminated
4 enrolled 5 charts
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Phase 1/2 Terminated
31 enrolled 17 charts
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Phase 1/2 Terminated
3 enrolled 7 charts
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Phase 1/2 Terminated
15 enrolled 9 charts
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Phase 1/2 Terminated
223 enrolled 50 charts
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
1 enrolled 3 charts
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Phase 1/2 Completed
64 enrolled 29 charts
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Phase 1/2 Completed
136 enrolled 30 charts
PIVOT IO 020
Phase 1/2 Terminated
15 enrolled 14 charts
REVEAL
Phase 1/2 Terminated
64 enrolled 22 charts
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Phase 1/2 Completed
50 enrolled 26 charts
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1/2 Completed
20 enrolled 9 charts
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase 1/2 Completed
58 enrolled 18 charts
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Phase 1/2 Completed
18 enrolled 13 charts
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Phase 1/2 Completed
28 enrolled 10 charts
MT-3724NHL001
Phase 1/2 Terminated
38 enrolled 20 charts
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGelâ„¢ in Subjects With Recurrent Glioma
Phase 1/2 Terminated
4 enrolled 5 charts
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 1/2 Completed
7 enrolled 10 charts
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
Phase 1/2 Completed
53 enrolled 17 charts
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
Phase 1/2 Terminated
3 enrolled 5 charts
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase 1/2 Completed
26 enrolled 13 charts
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Phase 1/2 Terminated
26 enrolled 20 charts
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
Phase 1/2 Terminated
19 enrolled 11 charts
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
Phase 1/2 Terminated
9 enrolled 12 charts
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Phase 1/2 Completed
70 enrolled 26 charts
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Phase 1/2 Completed
18 enrolled 11 charts
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase 1/2 Terminated
23 enrolled 13 charts
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Phase 1/2 Terminated
23 enrolled 12 charts
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Phase 1/2 Completed
17 enrolled 14 charts
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Phase 1/2 Terminated
6 enrolled 8 charts
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 1/2 Completed
90 enrolled 23 charts